Premium
Risperidone
Author(s) -
Cohen Lawrence J.
Publication year - 1994
Publication title -
pharmacotherapy: the journal of human pharmacology and drug therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.227
H-Index - 109
eISSN - 1875-9114
pISSN - 0277-0008
DOI - 10.1002/j.1875-9114.1994.tb02819.x
Subject(s) - pharmacology , extrapyramidal symptoms , haloperidol , antipsychotic , receptor , metabolite , chemistry , risperidone , antipsychotic agent , chlorpromazine , atypical antipsychotic , dopamine , medicine , schizophrenia (object oriented programming) , biochemistry , psychiatry
Risperidone, a benzisoxazole derivative, is a novel antipsychotic agent that has an extremely strong binding affinity for serotonin 5‐HT 2 receptors, a strong binding affinity for dopamine D 2 receptors, and a high affinity for α 1 ‐ and α 2 ‐adrenergic receptors and histamine H 1 receptors. Its affinity for serotonin receptors is approximately 200 times greater than that of haloperidol, and its dopamine antagonistic potency is comparable to that of haloperidol. Its major metabolite, 9‐hydroxyrisperidone, has similar pharmacologic activity, and thus the parent compound and metabolite form the active antipsychotic moiety. Clinical trials demonstrate that risperidone is an effective antipsychotic agent that improves negative as well as positive symptoms of schizophrenia. At recommended dosages, the frequency of extrapyramidal side effects is no greater than that seen with placebo. The drug appears to be an advance in the treatment of psychoses.